| DC Field | Value | Language |
|---|
| dc.contributor.author | Danilenko, L. M. | - |
| dc.date.accessioned | 2022-04-26T11:24:01Z | - |
| dc.date.available | 2022-04-26T11:24:01Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.citation | Danilenko, L.M. Doxorubicin-associated Cardiomyopathy: New Approaches to Pharmacological Correction Using 3-(2,2,2-trimethylhydrazinium) Propionate Derivatives / L.M. Danilenko // Research result: pharmacology and clinical pharmacology. - 2018. - Vol. 4, № 1.- P. 81-86. - DOI: 10.3897/rrpharmacology. 4.25530. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46375 | - |
| dc.description.abstract | The cardioprotective effect of the derivatives (nicotinate, 5-hydroxynicotinate) of 3-(2,2,2-trimethylhydrazini- um) propionate) and reference medicine meldonium in the case of doxorubicin (DOX) (20 mg/kg, intraperitoneally for 48 hours) cardiomyopathy was evaluated by the results of a functional test with high-frequency stimulation (480 bpm) | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | meldonium | ru |
| dc.subject | doxorubicin cardiopathy | ru |
| dc.subject | isolated rat heart | ru |
| dc.subject | doxorubicin-associated cardiomyopathy | ru |
| dc.title | Doxorubicin-associated Cardiomyopathy: New Approaches to Pharmacological Correction Using 3-(2,2,2-trimethylhydrazinium) Propionate Derivatives | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 4, № 1
|
